A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic Sclerosis
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary)
- Indications Systemic scleroderma
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 20 Dec 2022 Planned primary completion date changed from 14 Oct 2022 to 16 Jun 2023.
- 26 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2022 Planned End Date changed from 21 Jun 2024 to 5 Jul 2024.